Growth factors and their receptors: new targets for prostate cancer therapy.

@article{citeulike:1387564, abstract = {Stimulation of the signal transduction pathway of the epidermal growth-factor receptor (EGFR) tyrosine kinase family of receptors in tumor cells enhances cellular proliferation, prevents apoptosis, and promotes tumor-cell mobility, adhesion, and invasion. Therapeutic approaches used to target the EGFR and its signal transduction cascade include (1) monoclonal antibodies (eg, cetuximab [IMC-C225]) directed against the extracellular binding domain of the receptor; and (2) trastuzumab, a monoclonal antibody binding to the HER2 receptor; immunotoxin conjugates use an antibody directed against EGFR joined to a cell toxin. All are in clinical trials for a number of cancers, including prostate cancer. Antisense strategies are in preclinical development. Low-molecular-weight inhibitors of the EGFR tyrosine kinase also in clinical development include OSI-774, PD182905, PKI-166, CI-1033, and ZD1839. ZD1839 has shown encouraging results in patients with prostate cancer in phase 1 trials. mn}, address = {AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom.}, author = {Barton, J. and Blackledge, G. and Wakeling, A. }, citeulike-article-id = {1387564}, issn = {1527-9995}, journal = {Urology}, keywords = {cancer, cite, egfr, prostate, therapy}, month = {August}, number = {2 Suppl 1}, pages = {114--122}, posted-at = {2007-06-13 15:52:20}, priority = {2}, title = {Growth factors and their receptors: new targets for prostate cancer therapy.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/11502465}, volume = {58}, year = {2001} }

TY - JOUR ID - citeulike:1387564 L3 - citeulike-article-id:1387564 TI - Growth factors and their receptors: new targets for prostate cancer therapy. JF - Urology VL - 58 IS - 2 Suppl 1 SP - 114 EP - 122 AD - AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom. SN - 1527-9995 N2 - Stimulation of the signal transduction pathway of the epidermal growth-factor receptor (EGFR) tyrosine kinase family of receptors in tumor cells enhances cellular proliferation, prevents apoptosis, and promotes tumor-cell mobility, adhesion, and invasion. Therapeutic approaches used to target the EGFR and its signal transduction cascade include (1) monoclonal antibodies (eg, cetuximab [IMC-C225]) directed against the extracellular binding domain of the receptor; and (2) trastuzumab, a monoclonal antibody binding to the HER2 receptor; immunotoxin conjugates use an antibody directed against EGFR joined to a cell toxin. All are in clinical trials for a number of cancers, including prostate cancer. Antisense strategies are in preclinical development. Low-molecular-weight inhibitors of the EGFR tyrosine kinase also in clinical development include OSI-774, PD182905, PKI-166, CI-1033, and ZD1839. ZD1839 has shown encouraging results in patients with prostate cancer in phase 1 trials. mn KW - cancer KW - cite KW - egfr KW - prostate KW - therapy AU - Barton, J AU - Blackledge, G AU - Wakeling, A PY - 2001/08// UR - http://view.ncbi.nlm.nih.gov/pubmed/11502465 ER -